EPISODE · Jun 13, 2026 · 1H 4M
Ep 82: Best of ASCO: 2026
from Melanoma Matters · host Melanoma Matters Pod
In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.Studies discussed include:OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADAM phase 3 trial for MCC5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)Pilot neoadjuvant studies (NeoReNi, NeoINR)Time of day of infusion and immunotherapy efficacy
What this episode covers
In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.Studies discussed include:OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADAM phase 3 trial for MCC5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)Pilot neoadjuvant studies (NeoReNi, NeoINR)Time of day of infusion and immunotherapy efficacy
NOW PLAYING
Ep 82: Best of ASCO: 2026
No transcript for this episode yet
Similar Episodes
May 9, 2026 ·24m
May 7, 2026 ·56m
Apr 30, 2026 ·21m
Apr 27, 2026 ·19m
Apr 21, 2026 ·31m
Apr 21, 2026 ·53m